Effects of exercise on brain function in chronic cannabis users
Effect of Acute Exercise on Cognitive Functions and Blood Markers of Brain Plasticity in Regular Chronic Cannabis Users
NA · University Hospital, Lille · NCT06081218
This study is testing how exercise affects brain function and health in people who regularly use cannabis compared to those who don't.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 35 Years |
| Sex | All |
| Sponsor | University Hospital, Lille (other) |
| Locations | 1 site (Lille) |
| Trial ID | NCT06081218 on ClinicalTrials.gov |
What this trial studies
This study investigates how acute exercise influences cognitive functions and blood markers related to brain plasticity in individuals who regularly use cannabis. It aims to compare the endocannabinoid system's response to exercise between chronic cannabis users and non-users. Participants will undergo activity tests to assess these effects, focusing on the relationship between exercise and neurogenesis. The study seeks to understand the potential benefits of exercise in modifying the effects of chronic cannabis use on brain health.
Who should consider this trial
Good fit: Ideal candidates include chronic cannabis users who meet specific consumption criteria and healthy individuals with no recent cannabis use.
Not a fit: Patients with other substance use disorders, neurological disorders, or significant obesity may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into how exercise may improve cognitive function and brain health in chronic cannabis users.
How similar studies have performed: While the specific approach of this study is novel, previous research has indicated potential benefits of exercise on brain health, suggesting a promising area of investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Cannabis consumer group: * Cannabis consumption \> 100 times in lifetime, last exposure \< 7 days, and recent exposure \> 10 times in the month. * Positive toxicological urine test for ∆-9-THC. * Having a cannabis use disorder according to the CAST. Healthy group: * Negative urine toxicological test for cannabis. * No regular cannabis use for more than 6 months once in a lifetime. * No cannabis consumption in the 6 months preceding the study. Exclusion Criteria: For all subjects : * Disorders of use of other substances (alcohol, cocaine, opioid, or synthetic drugs). * Alcohol consumption greater than 30g per day (averaged over one week) and/or alcohol abuse the week preceding the visit. * Under medical treatment. * Presence of diagnosed neurological disorders. * Diagnosis of a psychotic picture entering axis I, DSM-5. * Chronic progressive disease or in remission. * Body mass index \> 30 kg/m2 (i.e. presence of obesity).
Where this trial is running
Lille
- CHU Lille — Lille, France (RECRUITING)
Study contacts
- Study coordinator: Olivier Cottencin, MD,PhD
- Email: olivier.cottencin@chru-lille.fr
- Phone: 0320445962
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cannabis User